SG11202005296SA - Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer - Google Patents

Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

Info

Publication number
SG11202005296SA
SG11202005296SA SG11202005296SA SG11202005296SA SG11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA
Authority
SG
Singapore
Prior art keywords
immunotherapy
combination therapy
treat cancer
progastrin antibody
progastrin
Prior art date
Application number
SG11202005296SA
Other languages
English (en)
Inventor
Alexandre Prieur
Original Assignee
Progastrine Et Cancers S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S A R L filed Critical Progastrine Et Cancers S A R L
Publication of SG11202005296SA publication Critical patent/SG11202005296SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202005296SA 2017-12-05 2018-12-05 Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer SG11202005296SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762594755P 2017-12-05 2017-12-05
PCT/EP2018/083651 WO2019110662A1 (en) 2017-12-05 2018-12-05 Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

Publications (1)

Publication Number Publication Date
SG11202005296SA true SG11202005296SA (en) 2020-07-29

Family

ID=64949216

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005296SA SG11202005296SA (en) 2017-12-05 2018-12-05 Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

Country Status (14)

Country Link
US (2) US11046758B2 (pl)
EP (1) EP3720879B1 (pl)
JP (1) JP7104153B2 (pl)
KR (1) KR102461238B1 (pl)
CN (1) CN111670197A (pl)
AU (1) AU2018379320B2 (pl)
CA (1) CA3084687C (pl)
DK (1) DK3720879T3 (pl)
ES (1) ES2920283T3 (pl)
PL (1) PL3720879T3 (pl)
PT (1) PT3720879T (pl)
SG (1) SG11202005296SA (pl)
TW (1) TWI763956B (pl)
WO (1) WO2019110662A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI763956B (zh) * 2017-12-05 2022-05-11 盧森堡商前胃泌激素及癌症有限公司 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法
KR20200144541A (ko) * 2018-02-27 2020-12-29 이씨에스-프로가스트린 에스에이 면역치료요법용 생체표지자로서 프로가스트린
CN111171146B (zh) * 2020-02-20 2022-03-04 西北农林科技大学 抗h9n2亚型禽流感病毒的纳米抗体、制备方法和应用
CN115466328A (zh) * 2021-06-11 2022-12-13 广东菲鹏制药股份有限公司 抗pd-1人源化抗体或其抗原结合片段及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5546806A (en) 1991-10-17 1996-08-20 Kain; Aron Z. Microwave vector displacement and acceleration transducer
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK1427828T3 (da) 2001-09-14 2010-07-19 Cellectis Tilfældig integration af et polynucleotid efter in vivo-linearisering
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
EP2567974A3 (en) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
EP2205752B1 (en) 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
CN102791735B (zh) * 2009-10-16 2016-05-18 瑟维尔实验室 抗前胃泌素的单克隆抗体及其用途
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
KR101570404B1 (ko) * 2010-03-24 2015-11-20 르 라보레또레 쎄르비에르 결장직장암 및 위창자암의 예방
AU2011284908B2 (en) * 2010-07-26 2015-05-21 Centre National De La Recherche Scientifique (Cnrs) Methods and compositions for liver cancer therapy
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SG11201702723VA (en) * 2014-10-29 2017-05-30 Five Prime Therapeutics Inc Combination therapy for cancer
PL3397967T3 (pl) * 2015-12-31 2021-06-28 Progastrine Et Cancers S.À R.L. Kompozycje i sposoby do wykrywania i leczenia raka przełyku
ES2899360T3 (es) * 2015-12-31 2022-03-11 Progastrine Et Cancers S A R L Composiciones y procedimientos para detectar y tratar cáncer gástrico
WO2017114972A1 (en) * 2015-12-31 2017-07-06 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
KR102616819B1 (ko) * 2017-03-30 2023-12-21 프로가스트린 에 캔서스 에스.에이 알.엘. 폐암을 치료하기 위한 조성물 및 방법
AU2018242152B2 (en) * 2017-03-30 2022-05-12 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
US11583576B2 (en) * 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
TWI763956B (zh) * 2017-12-05 2022-05-11 盧森堡商前胃泌激素及癌症有限公司 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法
KR20200144541A (ko) * 2018-02-27 2020-12-29 이씨에스-프로가스트린 에스에이 면역치료요법용 생체표지자로서 프로가스트린

Also Published As

Publication number Publication date
KR20200118409A (ko) 2020-10-15
JP7104153B2 (ja) 2022-07-20
CN111670197A (zh) 2020-09-15
KR102461238B1 (ko) 2022-11-01
DK3720879T3 (da) 2022-06-20
CA3084687A1 (en) 2019-06-13
EP3720879B1 (en) 2022-05-11
TW201927805A (zh) 2019-07-16
AU2018379320B2 (en) 2023-06-15
AU2018379320A1 (en) 2020-07-02
PT3720879T (pt) 2022-07-13
RU2020121176A (ru) 2022-01-10
ES2920283T3 (es) 2022-08-02
PL3720879T3 (pl) 2022-09-12
US11046758B2 (en) 2021-06-29
EP3720879A1 (en) 2020-10-14
JP2021505576A (ja) 2021-02-18
US20210324069A1 (en) 2021-10-21
WO2019110662A1 (en) 2019-06-13
US20210009680A1 (en) 2021-01-14
RU2020121176A3 (pl) 2022-04-27
TWI763956B (zh) 2022-05-11
CA3084687C (en) 2024-01-02

Similar Documents

Publication Publication Date Title
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL262562A (en) Combination of anti-pd-1 antibodies and radiation for cancer therapy
IL268138A (en) Combinations of cabozantinib and atezolizumab for cancer treatment
HK1247630A1 (zh) 用於增强癌症治療的效果的組合物和方法
GEP20217317B (en) Combination therapy for the treatment of cancer
IL313238A (en) Claudin 6 antibodies and methods of cancer treatment
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
IL248704A0 (en) Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2
IL275517A (en) Combined methods and treatment of cancer
SG11201707949XA (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
IL275913A (en) Methods and combined treatment for cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
LT3630112T (lt) Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui
IL274866A (en) Preparations and methods for the treatment of cancer
GB201717004D0 (en) Methods of cancer therapy
GB201711769D0 (en) Methods of cancer therapy
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer